Berberine vs Metformin at 12 months: HbA1c equivalence in Diabetes Care RCT
Source: Diabetes Care, vol. 49, May 2026
Summary
A double-blind randomized controlled trial published in Diabetes Care (May 2026) compares berberine (1500 mg/day) to metformin (1500 mg/day) in 180 women with PCOS and insulin resistance over 12 months. Primary outcomes: HbA1c reduction identical (-0.4 vs -0.4 points, p=0.92); HOMA-IR improvement comparable (-28% vs -31%, NS). Secondary outcomes favoring berberine: fewer GI side effects (nausea 18% vs 42%, p<0.001), higher 12-month adherence (87% vs 71%). Cycle regularity: 52% vs 58% normalization (NS). Important caveats: open-label formulations, predominantly East-Asian population (moderate generalizability), no pregnancy data. Author conclusion: berberine may be considered a reasonable alternative to metformin for patients who are intolerant or reluctant to use it, under medical supervision. This is a well-conducted trial but does not validate OTC berberine supplements as self-treatment.
Why it matters for you
This study does not mean you should replace metformin with berberine supplements. It suggests that for women who cannot tolerate metformin, berberine may be worth discussing with your doctor as a monitored alternative. OTC berberine supplements vary widely in purity and dose — never switch without medical guidance.